Advertisement

Topics

Companies Related to "Safety of Human Lactoferrin hLF1-11 for the Treatment of Infectious Complications Among Haematopoietic Stem Cell Transplant Recipients" [Most Relevant Company Matches] - Page: 2 RSS

16:30 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Safety of Human Lactoferrin hLF1-11 for the Treatment of Infectious Complications Among Haematopoietic Stem Cell Transplant Recipients" found in our extensive corporate database of over 50,000 company records.

Showing "Safety Human Lactoferrin hLF1 Treatment Infectious Complications Among" Companies 26–50 of 6,700+

Relevant

GenArraytion, Inc.

Based in Rockville, Md., GenArraytion, Inc. is a privately held, veteran-owned, small business dedicated to the development and commercialization of multiplexed molecular assays for infectious diseases. GenArraytion is dedicated to improving healthcare through the development and distribution of treatment-guiding molecular assays for infectious disease mar...


C3J Therapeutics, Inc.

C3J Therapeutics is a clinical-stage biotechnology company focused on improving human health through the development of targeted antimicrobials that treat infectious diseases and address microbial dybiosis associated with human disease. C3J Therapeutics is based in Los Angeles, California, with a 35,000 sq.ft. facility housing R&D and manufacturing. More i...

Creative Peptides develops pharmaceutical products

Creative Peptides develops pharmaceutical products based on C-peptide Our research will significantly improve on the treatment of long-term complications of type 1 diabetes. Complications of type 1 diabetes are currently not effectively and safely treatable and cause great suffering in afflicted patients as well as vast costs to society


Tigris Pharmaceuticals, Inc

Tigris Pharmaceuticals, Inc. is a venture-backed clinical-stage biopharmaceutical company that commercially develops innovative products for the treatment of important unmet medical needs in cancer and infectious diseases. Tigris is focusing its efforts on the development, testing and commercialization of its lead compound, A-007, as a non-invasive treatment for both pre-cancerous HPV-induced lesi...

NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on medical diagnostics. Its products offer accelerated detection and identification of microorganisms present in infectious and non-infectious human diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague. In addition to medical, Defense, and homeland security applications, NanoLogix technology is...

Achillion

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company’s discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections...

Green Hills Biotechnology

Green Hills Biotechnology (GHB) is a biopharmaceutical company based in Vienna, Austria. GHB uses its know-how in virology to develop and commercialize innovative products that offer cost-effective treatment for a wide range of diseases. The products under development by GHB are unique therapies against viral infectious diseases and cancer with the aim to significantly improve health and the quali...

GeneMax

GeneMax develops innovative immunotherapies in the fields of oncology and infectious disease. Our patented technology restores or increases antigen processing and antigen specific immune responses. GeneMax has demonstrated preclinical efficacy in animal models of lung cancer and melanoma as well as proof of principle for infectious disease pathogens.GeneMax’s program also includes developing a t...

ImmunoBiology Limited (ImmBio)

Limited [ImmBio] is a biotechnology company specialising in the treatment of infectious diseases and cancer. ImmBio's approach is to apply advances in the emerging science of Immunobiology to the development of treatments for infections diseases and cancer. Immbio is developing a proprietary vaccine technology based on these advances. The platform technology is called HspC™ vaccination. HspC...

Bio-Bridge Science

Bio-Bridge Science, Inc., a development stage biotechnology company, engages in the commercial development of vaccines for the prevention and treatment of human infectious diseases. The company is currently developing and commercializing HIV-PV Vaccine I to prevent and treat infection by the human immunodeficiency virus (HIV). It develops HIV vaccines for both preventive and therapeutic purposes. ...

Celldex therapeutics

Celldex is a biotechnology company focused on the discovery, development and commercialization of novel immunotherapeutics including human monoclonal antibodies for the treatment of cancer, infectious diseases, and immune system disorders. We are advancing a pipeline of clinical and pre-clinical product candidates.Our proprietary core technology utilizes human monoclonal antibodies to directly tar...

Kenta Biotech

Kenta Biotech is pioneering the research and development of fully human IgM antibodies that are desperately needed for the treatment of severe hospital-acquired infections. Antibodies generated from Kenta's proprietary MabIgX® technology effectively target bacteria independently of resistance to antimicrobial agents. Furthermore, the MabIgX® technolo...

Morphotek Inc.

Morphotek is a biopharmaceutical company developing therapeutic monoclonal antibodies through the use of a proprietary human antibody technology. The company employs its technology to discover and develop optimized antibodies for the treatment of cancer, inflammatory, and infectious diseases. Morphotek currently has two products in clinical development and is positioned to file INDs for additional...

NewLink Genetics

NewLink Genetics is a private biopharmaceutical company with innovative technologies that are powering a late stage pipeline targeted at tough to treat cancers and infectious disease. NewLink's two complementary technology platforms target separate mechanisms that are commonly utilized by different cancer types to avoid immune system detection and destruction. The company's HyperAcute® cancer imm...

Corporate Communications, CEL-SCI Corporation

CEL-SCI Corporation (AMEX: CVM), a biotechnology company, was formed in 1983. CEL-SCI is involved in the research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The Company’s core capabilities include drug discovery, research, development and manufacturing of complex biological substances.Recurrence of cancer is the greatest fear for the cancer patient...

Visterra, Inc.

Visterra discovers and develops novel drugs for the prevention and treatment of major diseases. The company’s proprietary platform generates unique structural information that identifies novel drug target sites and guides the design of drugs to effectively combat disease. The company’s lead product candidate, VIS410, is a broad spectrum monoclona...

Visterra Inc.

Visterra discovers and develops novel drugs for the prevention and treatment of major diseases. The company’s proprietary platform generates unique structural information that identifies novel drug target sites and guides the design of drugs to effectively combat disease. The company’s lead product candidate, VIS410, is a broad spectrum monoclona...

Scancell Holdings Plc

Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and has recently entered clinical trials.

Immunome

Immunome is a discovery stage biopharmaceutical company that has created a proprietary Native Human Monoclonal Antibody (N-huMAB) platform. N-huMAbs are the exact structures created by nature and possess the natural safety and power of the human immune system. The Immunome method is an exclusive, optimized hybridoma process that produces affinity-matured I...

Robert Koch-Institut

The Robert Koch Institute is one of the most important institutions for health protection in Germany. It serves the Federal Ministry of Health as a central scientific institution in the field of biomedicine. The Institute links risk research with political advice. Its tasks include protection against infectious diseases, analysis of the health situation in Germany and the safety assessment of gene...

ISRTP

The purpose of the Society is to provide an open public forum for policy makers and scientists promoting sound toxicologic and pharmacologic science as a basis for regulation affecting human safety and health, and the environment. - Adopted December 12, 2003.ObjectivesIn order to fulfill the Society's Mission Statement, three objectives must be met.The first is identifying and prioritizing scienti...

Infectious Diseases Society of America

The Infectious Diseases Society of America (IDSA) represents physicians, scientists and other health care professionals who specialize in infectious diseases. IDSA’s purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases

Chembio Diagnostics

Chembio Diagnostic Systems, Inc. is a US company serving the increasing global demand for rapid tests needed for the effective prevention and treatment of infectious diseases, and other conditions. Chembio's focus is on developing, manufacturing and marketing tests for the rapid, simple and cost-effective detection of HIV, Tuberculosis (human and veterinary), and certain other Neglected Diseases. ...

Sensorion

Spun off from Inserm (the French institute of health and medical research) in 2009, Sensorion is a biotech that specializes in the treatment of pathologies of the inner ear such as acute vertigo, tinnitus and hearing loss. Backed by its pharmaceutical R&D experience and a comprehensive technology platform, Sensorion is developing three drug candidate progr...

LigoCyte Pharmaceuticals, Inc.

LigoCyte is breaking new ground in the treatment of inflammatory and infectious disease. We have produced a number of novel drug compounds to modify immune responses by focusing on cell binding interactions and their role in the immune system. Immunomodulatory drugs represent one of the most exciting areas of pharmaceutical research today, addressing the disease process itself rather than simply t...


More From BioPortfolio on "Safety of Human Lactoferrin hLF1-11 for the Treatment of Infectious Complications Among Haematopoietic Stem Cell Transplant Recipients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks